Value
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 3.1 |
| P/S | 0.9 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 5.0 |
| PEG | 5.1 |
| Analyst target | 4.0 |
- ▸Forward P/E: 24.9x
- ▸PEG: 1.48
LLY · Why this verdict
Why Eli Lilly and (LLY) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Eli Lilly is a high-quality healthcare franchise with 56% revenue growth, a wide economic moat, and four consecutive double-digit earnings beats, but the stock has effectively reached the analyst consensus price target with only 0.9% headroom remaining — the setup favors accumulation on weakness rather than initiating at current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business carries a wide economic moat with 35% net margins and a Rule of 40 score of 68 — an exceptional combination that distinguishes the franchise within healthcare and justifies a structural valuation premium over peers. Quality breakdown | Net margin stays above 30% and the Rule of 40 remains above 55 over the next 4 quarters, confirming that profitability and growth continue to reinforce each other. | →Stable |
| CounterFree cash flow is converting at only 36% of net income — a flagged quality concern — and the balance sheet carries a debt-to-equity ratio of 1.4; if earnings growth moderates and FCF does not recover, the current premium multiple may face downward pressure. | ||
The company has beaten consensus estimates in each of the past 4 quarters, averaging roughly 14.5% upside to expectations, with the most recent quarter delivering 16.9% above the estimate. This consistent pattern of under-promising and over-delivering supports the premium multiple even at elevated price levels. Earnings | Average EPS surprise remains above 10% over the next 4 quarters with no misses, sustaining the positive earnings revision cycle. | →Stable |
| CounterWith analyst targets already reached and only 0.9% headroom remaining to the take-profit level, continued beat delivery may already be fully discounted, leaving limited room for additional multiple expansion from current prices. | ||
Revenue has grown 56% year over year, well above the typical rate for a large-cap pharmaceutical company, supporting premium multiple sustainability if this trajectory continues to outpace consensus expectations. Growth breakdown | Revenue growth stays above 30% year over year for the next 2 reported quarters, sustaining the exceptional growth narrative. | →Stable |
| CounterThe leverage on the balance sheet (debt-to-equity at 1.4) represents a financial constraint that could limit reinvestment capacity if growth moderates; higher debt service may reduce flexibility at the moment it is most needed. | ||
With the stock sitting just below its analyst consensus price target — approximately 0.9% of headroom remaining to the take-profit level — the near-term reward is thin even as the risk/reward structure remains favorable at roughly 2.9-to-1. The setup favors patience over initiating new exposure at these levels. Warnings | A pullback toward the 50-day moving average entry zone restores a more attractive risk/reward profile for incremental positions. | →Stable |
| CounterA wide-moat franchise growing at 56% year over year can sustain and extend premium valuations; if analysts raise their consensus targets on continued beat delivery, the apparent ceiling resets and the current price becomes a compelling entry in retrospect. | ||
The business carries a wide economic moat with 35% net margins and a Rule of 40 score of 68 — an exceptional combination that distinguishes the franchise within healthcare and justifies a structural valuation premium over peers.
→StableQuality breakdown
- Expectation
- Net margin stays above 30% and the Rule of 40 remains above 55 over the next 4 quarters, confirming that profitability and growth continue to reinforce each other.
CounterFree cash flow is converting at only 36% of net income — a flagged quality concern — and the balance sheet carries a debt-to-equity ratio of 1.4; if earnings growth moderates and FCF does not recover, the current premium multiple may face downward pressure.
The company has beaten consensus estimates in each of the past 4 quarters, averaging roughly 14.5% upside to expectations, with the most recent quarter delivering 16.9% above the estimate. This consistent pattern of under-promising and over-delivering supports the premium multiple even at elevated price levels.
→StableEarnings
- Expectation
- Average EPS surprise remains above 10% over the next 4 quarters with no misses, sustaining the positive earnings revision cycle.
CounterWith analyst targets already reached and only 0.9% headroom remaining to the take-profit level, continued beat delivery may already be fully discounted, leaving limited room for additional multiple expansion from current prices.
Revenue has grown 56% year over year, well above the typical rate for a large-cap pharmaceutical company, supporting premium multiple sustainability if this trajectory continues to outpace consensus expectations.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 30% year over year for the next 2 reported quarters, sustaining the exceptional growth narrative.
CounterThe leverage on the balance sheet (debt-to-equity at 1.4) represents a financial constraint that could limit reinvestment capacity if growth moderates; higher debt service may reduce flexibility at the moment it is most needed.
With the stock sitting just below its analyst consensus price target — approximately 0.9% of headroom remaining to the take-profit level — the near-term reward is thin even as the risk/reward structure remains favorable at roughly 2.9-to-1. The setup favors patience over initiating new exposure at these levels.
→StableWarnings
- Expectation
- A pullback toward the 50-day moving average entry zone restores a more attractive risk/reward profile for incremental positions.
CounterA wide-moat franchise growing at 56% year over year can sustain and extend premium valuations; if analysts raise their consensus targets on continued beat delivery, the apparent ceiling resets and the current price becomes a compelling entry in retrospect.
Per-dimension breakdown
Quality
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.5 |
| FCF quality | 2.9 |
| Moat | 7.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 107%
- ▸Strong margins: 35%
- ▸Earnings quality RED FLAG: 36% FCF/NI
- ▸Wide economic moat
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 56% YoY
Momentum
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.6 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.8 |
| Analyst rating | 7.5 |
| Price target | 6.3 |
- ▸LLM news sentiment: +0.37 (n=9)
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸Negligible insider selling — $18,631,462 (0.002% of mkt cap)
Peer rank
5.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.3 |
| quality rank | 9.0 |
| growth rank | 9.4 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.8 |
| support resistance | 5.0 |
| 52w position | 8.9 |
| gap | 5.0 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.5 |
| days to cover | 8.1 |
| volatility | 4.2 |
| put call | 3.7 |
| implied vol | 5.8 |
| beta | 9.9 |
| debt equity | 4.2 |
| news risk | 3.0 |
Catalyst
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 5.2 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 63.0%
How the verdict was assembled
Engine trigger
Fundamentals strong but target reached (-1.8% upside).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP|V8:TARGET_REACHED|ENTRY_STICKY:WITHIN_BANDPassed (6)
- MOMENTUM:5.3>=4.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.3=NEGATIVE
Warning (1)
- MOMENTUM:5.3<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-0.28
Upside
-1.8%
Downside
6.6%
Sizing output
STARTER
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityCONSERVATIVE — Beta 0.52<0.8, Div 63.0%, Q=8.2
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 8.2 and growth 10.0 both clear their thresholds, with asymmetric R:R of -0.28 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 8.2, and Catalyst at 7.2; the weakest are Value at 3.4, Insider at 5.0, and Momentum at 5.3. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.28 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has beaten consensus estimates in each of the past 4 quarters, averaging roughly 14.5% upside to expectations, with the most recent quarter delivering 16.9% above the estimate. This consistent pattern of under-promising and over-delivering supports the premium multiple even at elevated price levels.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2The business carries a wide economic moat with 35% net margins and a Rule of 40 score of 68 — an exceptional combination that distinguishes the franchise within healthcare and justifies a structural valuation premium over peers.
Trip ifNet margin compresses below 28% for 2 consecutive quarters.
- P3Revenue has grown 56% year over year, well above the typical rate for a large-cap pharmaceutical company, supporting premium multiple sustainability if this trajectory continues to outpace consensus expectations.
Trip ifRevenue growth falls below 20% year over year for 2 consecutive quarters.
- P4With the stock sitting just below its analyst consensus price target — approximately 0.9% of headroom remaining to the take-profit level — the near-term reward is thin even as the risk/reward structure remains favorable at roughly 2.9-to-1. The setup favors patience over initiating new exposure at these levels.
Trip ifUpside to analyst consensus price target exceeds 15% for 2 consecutive months.